Cann Global Limited Overview
Cann Global Limited is a Sydney-based micro-cap that turned a dormant bauxite explorer (Queensland Bauxite) into a diversified hemp, plant-based food, cosmeceutical and medicinal cannabis group between 2016 and 2019. At its peak it had a hemp-seed and chia health-food wholesale business (T12 Holdings / Organic Markets Direct, sold into Costco Australia and exported to Vietnam), a 55%-owned Thai hemp cultivation and extraction services venture, a 50:50 medicinal-tablet JV with Canada's Canntab Therapeutics, a 50:50 skincare JV with Israel's Pharmocann (later the Fuss Pot brand), and Technion-linked multiple sclerosis research. It never reached scale. Revenue peaked at A$1.78m in FY2020 and fell to A$0.56m in FY2022. Cumulative losses reached A$50.7m, funded by repeated, highly dilutive equity raisings. A prolonged voluntary suspension from September 2022 tied to an unconsummated Thailand acquisition, unpaid ASX fees and unlodged FY2023 accounts led to removal from the ASX in March 2024. It now survives only as a registered unlisted shell-like entity.
Company's own description (FY2021/FY2022 filings, paraphrased). Cann Global described itself as a medicinal cannabis and natural food and beauty products business operating in the health and wellness industry. It stressed partnerships with specialists in Australia, the USA, Israel, Asia and Canada, and said it worked within relevant legislation to give practitioners, patients and consumers access to safe, effective and sustainable products [4E-FY21]. The FY2022 financial statements describe the group as a for-profit entity engaged mainly in the legal growing and cultivation of hemp and medicinal cannabis products and in mineral exploration in Australia [4E-FY22].
Operating divisions as presented to investors (FY2020–FY2022):
-
Food (Health Foods) — hemp seed and chia products (seed, oil, protein, flour, capsules, by-products, smoothie blends) through T12 Holdings / Organic Markets Direct and the Vitahemp, EM Super Foods, Australian Grown Naturals, Black Bag and later Grass Roots brands. This was the only consistent revenue generator.
-
Hemp Cultivation & Processing — hemp hulling in Australia (Hemp Hulling Co (QLD) Pty Ltd, 55%) and broad-acre CBD hemp services in Asia through Cann Global Thailand (55%) and Cann Global Asia (55%).
-
Skincare / Cosmeceutical — premium hemp-seed-oil skincare first developed in the 50:50 Pharmocann JV, later sold under the wholly owned Fuss Pot brand after the JV was dissolved in July 2022.
-
Medicine — the Canntab Therapeutics Australia JV (50:50), which imported pharmaceutical-grade CBD hard tablets (later branded Instacann, using SMEDDS technology) via the TGA Special Access Scheme B and Authorised Prescriber pathways, plus MS-focused cannabis research with Technion (Israel) and NICM.
-
Mining — the residual South Johnstone bauxite project, Queensland (EPM 18463, later referenced as MDL 2004), carried at A$2.28m.
Revenue model. Revenue was almost entirely product sales (goods transferred at a point in time). In FY2022, goods made up A$537.5k of A$562.3k (95.6%); services were A$7.6k and management/rent recharges A$17.3k [4E-FY22]. There was no subscription or licensing revenue. Thai cultivation services (FY2020 services revenue A$151.2k) and a Thai "plant-funding" investor model (FY2022 liability A$254.8k) were the only service-type streams.
Value-chain position. The company's main role was mid-stream wholesale and branding of commodity health foods, buying seed and sub-contracting farmers rather than growing at scale. In FY2021 it suspended its own hemp-seed cultivation and seed-bank breeding programme in favour of contract farming [4E-FY21]. In medicinal cannabis it was a downstream importer/distributor of a partner's product, not a licensed manufacturer.
Customer types and end-markets. Retail (Costco Australia; direct-to-consumer web stores), wholesale/white-label distributors, export distributors (Epco Food Co, Vietnam), equine feed (white label), Thai licensed cultivators (AA Bio Co Ltd, Green Pharma Botanical), a US seed buyer (Naga Organics LLC), and prescribing doctors/pharmacies via the TGA access schemes.
Independent characterisation. Cann Global was a sub-scale holding company with many small, loosely connected ventures across three continents and no defensible core asset. Its corporate overhead (A$3.5–4.2m a year in the corporate segment, FY2020–FY2022) was 2–7 times group revenue. The business depended on related-party service arrangements (Australian Gemstone Mining Pty Ltd, controlled by the founder) and on frequent, deeply discounted equity issues. It was effectively a cash shell with a modest food distribution business attached by FY2022. At 30 June 2022, cash of A$9.24m was about 97% of net assets [4E-FY22].
Strategy
Stated strategy themes (paraphrased from FY2020–FY2022 releases):
FY2020: Grow food division sales with an export focus (China, Southeast Asia); bring Canntab tablets and other medical cannabis products into Australia; expand Asian operations; move towards profitability through operational efficiency [4E-FY20].
FY2021: Refocus on direct-to-consumer channels in Australia and abroad; rationalise the product and brand portfolio towards higher-margin lines; launch premium hemp skincare in Australia and Europe; launch Canntab tablets; prepare an MS clinical trial with NICM; keep little or no debt [4E-FY21].
HY2022: The CEO cited three new revenue streams launched and "four growth pillars" focused on differentiation [HY22].
FY2023: Pivot to acquisition-led transformation: assess several "value-based" acquisition proposals, then exclusive due diligence on Thai cannabis assets intended to sell into Thailand and later Europe and Australia; brand streamlining and cost cuts to preserve cash [ASX-ANN].
Initiatives announced in the last 24 months (October 2024 – October 2026). None publicly announced. The company has been unlisted since March 2024 and has issued no public updates since then. The only public records in the window are ASIC registry actions (strike-off initiated January 2026, reversed February 2026) [DL].
ESG commitments. None disclosed.
Medium-term financial targets / guidance. Never provided.
Products & Services
Pricing models were not publicly disclosed for any product line. Launch years are taken from ASX releases where available.
Food division (Cannabis segment)
| Product / brand | Description & specifications | Target customer | Launch / latest year | Flagship offerings & notes | Source |
|---|---|---|---|---|---|
| VitaHemp hemp seed oil capsules | Organic premium hemp seed oil daily capsule | Retail (Costco), consumers | Costco first order Aug 2019 (6,900 bottles) | Flagship Costco SKU | [BNA], [4E-FY20] |
| Organic Hemp Protein powder | Hemp protein powder | Costco and retail | Added to Costco range FY2020 | FY2022 revenue A$94.2k | [4E-FY20], [4E-FY22] |
| Hulled hemp seed (hearts) | Food-grade hulled hemp seed; raw seed sourced from contract farmers (e.g., Midlands Tasmania supply agreement) | Wholesale, export (Vietnam), retail | FY2020 peak (A$1.59m seed sales) | Largest single line in FY2020 | [4E-FY20], [4E-FY21] |
| Hemp seed oil | Culinary/nutritional oil | Retail/wholesale | Ongoing | FY2021 A$291.8k; FY2022 A$108.9k | [4E-FY21], [4E-FY22] |
| Hemp flour | Milled flour | Retail/wholesale | Ongoing | FY2022 A$10.1k | [4E-FY22] |
| Hemp by-products | Processing by-products | Wholesale/feed | Ongoing | FY2021 A$57.2k | [4E-FY21] |
| Smoothie blends | Hemp-based blends | Retail | Discontinued by FY2022 | FY2021 A$1.7k | [4E-FY21] |
| Chia seed | Wholesale chia (Organic Markets Direct) | Wholesale, Vietnam export | Ongoing | FY2021 A$381.6k; FY2022 A$105.7k | [4E-FY21], [4E-FY22] |
| Chia oil soft-gel capsules | Plant-based omega-3 capsule; company claimed the highest omega-3 content of any plant-based product on the market | Costco, white-label distributor | Developed FY2020, Costco order FY2021 | Also white-labelled | [4E-FY20], [4E-FY21] |
| Chia/hemp equine feed | Horse feed product | White-label customer | FY2021 | White label only | [4E-FY21] |
| Hemp pet food range | Pet food | Retail | Development FY2020 | Commercial outcome not disclosed | [4E-FY20] |
| Grass Roots | Plant-based, nutritionist-endorsed health-food range for everyday meals and snacks; replaced older brand portfolio after FY2021 rationalisation | Retail/DTC consumers | c. FY2022 | Core consumer food brand by 2022 | [SWS], profile data |
| EM Super Foods, Australian Grown Naturals (AGN), Black Bag | Legacy T12 health-food brands (superfoods, Australian-grown lines) | Retail/wholesale | Acquired Jul 2019 | Rationalised from FY2022 | [4E-FY20] |
| Organic Markets Direct (OMD) | Health-food wholesaler: hemp seed products, chia, Green Leaf Stevia, cacao and similar | Retailers, wholesalers | Acquired Jul 2019 | Channel business | [4E-FY20] |
Hemp cultivation & processing
| Offering | Description | Customer | Year | Notes | Source |
|---|---|---|---|---|---|
| Hemp hulling (Hemp Hulling Co, Coolum Beach QLD) | Food-grade hemp seed dehulling | Internal supply and third parties | 55% from Jul 2019 | Voluntary administration Mar 2022 | [4E-FY20], [4E-FY22] |
| Thai cultivation & extraction services (CGT) | Full-service hemp cultivation/extraction under licences held by Thai partners (AA Bio Co Ltd, Green Pharma Botanical) | Thai licence holders | From Jun 2020 | First-period profit A$143.3k | [4E-FY20], [4E-FY21] |
| Auto-flowering feminised CBD hemp seed | Seed genetics for outdoor off-season cultivation in Asia; 5m seeds ordered by Naga Organics LLC (USA), valued at US$750k | Growers/seed buyers | FY2020 | Delivery of the full order not disclosed | [4E-FY20] |
| Plant-funding programme (Thailand) | Investors fund cultivation per plant and receive a fixed fee per plant after harvest/extraction | Investors (first UK investor in FY2022) | FY2021 | A$203.5k received FY2022; recorded as a liability | [4E-FY21], [4E-FY22] |
| Seed bank & plant genetics (MCL) | Cannabis/hemp genetics, including the "Tabulum Project" triploid trials | Internal R&D | Acquired with MCL | Fully written down by FY2021 | [ASX-ANN], [4E-FY21] |
Skincare (Cosmeceutical)
| Offering | Description | Customer | Year | Notes | Source |
|---|---|---|---|---|---|
| Fuss Pot | Hemp-powered premium skincare: an oil, a serum and a cream with hemp seed oil as the main active and Australian native botanicals; organic certification pursued | Consumers (DTC web, Australia), EU B2B | Soft launch Paris CBD Expo Oct 2021 and Canberra Nov 2021; CBD-based range shown in Italy May 2022 | Moved to 100% ownership after Pharmocann JV dissolved Jul 2022 | [4E-FY21], [4E-FY22], [SWS] |
Medicine
| Offering | Description | Customer | Year | Notes | Source |
|---|---|---|---|---|---|
| Canntab CBD tablets (12.5 mg, 25 mg) | Pharmaceutical-grade, uniform-dose hard cannabinoid tablets made in Canada | Patients via TGA SAS-B and Authorised Prescriber schemes; prescribers/pharmacies | First shipment cleared Aug 2021 | Distributed with MedCan's "Cann I help" prescribing service until MedCan terminated Jul 2022 | [4E-FY21], [4E-FY22] |
| Instacann | Brand combining natural cannabis extracts with a self-micro-emulsifying drug delivery system (SMEDDS) tablet | Prescribers/patients | c. 2022 | Positioned as an alternative to oils | Profile data (MarketScreener) |
| MS cannabis chemovar (Technion / NICM) | Strain identified by Dr Dedi Meiri's Technion lab as stopping, and in some cases reversing, MS progression in vitro and in vivo; draft human trial protocol written by NICM Health Research Institute | Future pharmaceutical | Results Jun 2020; protocol 2021 | Commercial rights held via the Pharmocann JV; no human trial start disclosed | [ASX-ANN], [4E-FY21] |
| Olivia's Choice formula | Medical cannabis formulation IP licensed from director John Easterling | Patients | Agreement Dec 2019 | Not launched; raw materials could not be imported under Australian law | [4E-FY20], [4E-FY21] |
Mining
| Asset | Description | Status | Source |
|---|---|---|---|
| South Johnstone Bauxite Project, Queensland | Bauxite exploration tenement EPM 18463 (renewed to 25 May 2022 after part relinquishment). FY2022 notes refer to MDL 2004, renewed to 31 Oct 2022 | Carrying value A$2.278m at 30 Jun 2022. Current tenure status not publicly disclosed | [4E-FY21], [4E-FY22] |
Financial Narrative
Margins and growth
Revenue CAGR FY2019–FY2022 is +5.4% a year (A$480.6k to A$562.3k over three years). This hides a spike-and-collapse: revenue rose +270.7% in FY2020 with the T12 acquisition, then fell −16.5% in FY2021 (COVID impact on Vietnam export partner Epco and less Thai service income) and −62.2% in FY2022 (deliberate portfolio rationalisation, loss of export sales, Hemp Hulling Co administration). FY2019 revenue growth is shown as 0 because FY2018 trading revenue is not available in the sources reviewed.
Expense composition
Impairments by year:
-
FY2019: A$2,902.9k fair-value loss on financial assets plus A$485.0k receivables impairment plus A$13.7k exploration written off.
-
FY2021: A$308.6k exploration, A$242.7k receivables, A$200.0k Koegas investment and A$138.0k seed bank.
-
FY2022: A$2,691.3k goodwill, A$1,880.9k loss on HHC disposal, A$270.1k JV investments and A$31.4k receivables.
Balance sheet
Notes:
-
The FY2020 going-concern note refers to "net current liabilities of $2,042,216". The balance sheet itself shows positive working capital of the same amount (current assets A$8,770.8k less current liabilities A$6,728.6k). This is a wording error in the filing.
-
At 30 June 2018 (opening FY2019 balances), cash was A$6,409.3k and total equity A$11,549.4k [4E-FY20].
Cash flow
FY2021 capex = PP&E A$7.2k + intangibles A$37.9k + exploration A$136.0k. FY2022 capex = PP&E A$27.2k + intangibles A$69.1k + capital works A$11.3k. Investment in equity-accounted JVs (A$390.6k in FY2021; A$461.1k in FY2022) is excluded from capex.
Commentary on trends, inflections and drivers
Revenue. The single inflection was the T12 acquisition, effective 1 July 2019. T12 alone contributed A$1.60m of FY2020 revenue [4E-FY20]. After FY2020 the food business shrank on three fronts:
-
Export sales to Vietnam collapsed when Epco was disrupted by COVID-19.
-
Management rationalised the product range in Q4 FY2021, accepting lower revenue for higher margins.
-
In FY2022 the group lost Hemp Hulling Co to administration and exited low-margin lines.
Revenue at A$0.56m in FY2022 was only 17% above FY2019, before any acquisitions.
Gross margin. Gross margin peaked at 26.4% in FY2020 and turned negative (−13.9%) in FY2022. Seed and related product cost (A$573.6k) exceeded total sales (A$562.3k), which points to inventory clearance or write-downs at below cost [4E-FY22].
Operating losses. Operating losses were driven by overhead, not product economics. In FY2022, administrative and corporate expenses (A$2.25m), directors' fees (A$0.41m) and share-based payments (A$0.42m) together were 5.5 times revenue. FY2020 losses were inflated by A$2.13m of research spending (Technion MS programme) and A$2.01m of finance costs on high-cost convertibles (L1 Capital, Obsidian) and seed-capital loans carrying 20% conversion discounts or premiums.
Balance sheet. Converting about A$3.73m of convertibles and loans to equity in FY2021, plus A$6.65m of new equity, made the balance sheet effectively debt-free. Cash peaked at A$10.57m in June 2021. The FY2022 write-off of all A$4.32m of goodwill (MCL, T12, HHC) left the company with few assets other than cash, inventory and the bauxite tenement.
Cash burn. Operating cash burn stabilised at about A$2.6–2.7m a year in FY2021–FY2022. At that rate the A$9.24m cash balance at 30 June 2022 implied about 3.4 years of runway. No figures after the Q2 FY2023 Appendix 4C (lodged 1 Feb 2023) have been located, so the current cash position is not publicly disclosed.
Dilution. Share count (consolidation-adjusted) rose about 4 times between June 2019 and June 2022. Equity was issued at A$0.035 (August 2019), then A$0.005 (FY2021) and about A$0.003 (October 2021), all pre-consolidation. Each raising was at a lower price than the last.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Cannabis segment revenue (AUD K) | 1,805.0 | 1,488.0 | 562.3 |
Mining segment revenue (AUD K) | 0 | 0 | 0 |
Corporate segment revenue excl interest (AUD K) | 0 | 0 | 138.2 |
Cannabis share of operating revenue (%) | 100 | 100 | 100 |
Cannabis segment revenue YoY growth (%) | 275.5 | -17.6 | -62.2 |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Cannabis segment loss before tax (AUD K) | -5,016.9 | -2,068.2 | -642.6 | -5,358.2 |
Mining segment loss before tax (AUD K) | -26.7 | -4.6 | -311.3 | -1.9 |
Corporate segment loss before tax (AUD K) | -4,190.8 | -5,978.0 | -3,816.7 | -3,719.2 |
Group loss before tax (AUD K) | -9,234.4 | -8,050.8 | -4,770.5 | -9,079.3 |
Cannabis segment margin on revenue (%) | -1,043.8 | -114.6 | -43.2 | -952.8 |
Segment Assets & Liabilities
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Cannabis segment assets (AUD K) | 3,389.5 | 6,497.8 | 5,800.0 | 1,584.2 |
Mining segment assets (AUD K) | 2,260.7 | 2,471.9 | 2,288.9 | 2,287.8 |
Corporate segment assets (AUD K) | 5,183.8 | 7,578.2 | 10,647.4 | 9,281.1 |
Group Entities
| Entity | Country | Ownership (%) | Role |
|---|---|---|---|
Cann Global Limited | Australia | Parent | Listed holding company |
South Johnstone Bauxite Pty Ltd | Australia | 100 | Bauxite tenement holder |
Volcan Queensland Bauxite Pty Ltd | Australia | 100 | Legacy mining |
Medical Cannabis Limited | Australia | 100 | Seed bank, cannabis IP, research parent |
Medical Cannabis Research Group Pty Ltd | Australia | 100 | Technion/MS research contracting entity |
Vitahemp Pty Ltd | Australia | 95 | Vitahemp food brand |
Vitaseeds Pty Ltd | Australia | 100 | Seeds |
Vitacann Pty Ltd | Australia | 100 | Cannabis products |
T12 Holdings Pty Ltd | Australia | 100 | Food division (Organic Markets Direct) |
Hemp Hulling Co (QLD) Pty Ltd | Australia | 55 (control lost Mar 2022, in voluntary administration) | Hemp seed hulling |
Cann Global Asia Pty Ltd | Australia | 55 | Laos hemp project (abandoned) |
Cann Global Thailand Pty Ltd | Australia | 55 | Thai cultivation/extraction services |
Medical Cannabis (Cambodia) Co., Ltd | Cambodia | 51 | Dormant Asian vehicle |
Canntab Therapeutics Australia | Australia | 50 (equity-accounted JV) | Cannabinoid tablet distribution |
Pharmocann Global Pty Ltd | Australia | 50 (dissolved 7 Jul 2022) | Skincare JV |
Income Statement and Per-Share Data
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Revenue (AUD K) | 480.6 | 1,781.7 | 1,488.0 | 562.3 |
Cost of goods sold (AUD K) | 562.2 | 1,311.9 | 1,162.3 | 640.5 |
Gross profit (AUD K) | -81.6 | 469.9 | 325.7 | -78.2 |
Other income incl FX (AUD K) | 0 | 30.6 | 595.8 | 11.3 |
Total operating expenses (AUD K) | 8,364.5 | 6,667.4 | 5,756.1 | 9,169.3 |
Operating income EBIT (AUD K) | -8,446.0 | -6,167.0 | -4,834.6 | -9,236.2 |
Depreciation and amortisation (AUD K) | 62.1 | 79.1 | 155.0 | 232.5 |
EBITDA computed (AUD K) | -8,384.0 | -6,087.8 | -4,679.6 | -9,003.7 |
Finance income (AUD K) | 123.3 | 124.7 | 163.6 | 191.4 |
Finance costs (AUD K) | 911.6 | 2,008.6 | 99.5 | 34.6 |
Pre-tax income (AUD K) | -9,234.4 | -8,050.8 | -4,770.5 | -9,079.3 |
Income tax (AUD K) | 0 | 0 | 0 | 0 |
Net income total (AUD K) | -9,234.4 | -8,050.8 | -4,770.5 | -9,079.3 |
Net income attributable to members (AUD K) | -6,434.9 | -8,012.1 | -4,621.4 | -8,218.0 |
Net loss attributable to non-controlling interests (AUD K) | -2,799.4 | -38.7 | -149.1 | -861.4 |
EPS basic as reported (AUD cents) | -0.57 | -0.26 | -0.10 | -3.68 |
EPS diluted as reported (AUD cents) | -0.57 | -0.26 | -0.10 | -3.68 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Revenue growth YoY (%) | 0 | 270.7 | -16.5 | -62.2 |
Gross margin (%) | -17.0 | 26.4 | 21.9 | -13.9 |
Operating margin (%) | -1,757.2 | -346.1 | -324.9 | -1,642.5 |
EBITDA margin (%) | -1,744.3 | -341.7 | -314.5 | -1,601.2 |
Net margin total loss (%) | -1,921.3 | -451.9 | -320.6 | -1,614.6 |
Key Financials
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Administrative and corporate (AUD K) | 1,708.5 | 1,673.4 | 2,568.0 | 2,248.7 |
Directors fees CGB (AUD K) | 714.0 | 684.0 | 699.7 | 408.4 |
Research costs (AUD K) | 407.9 | 2,130.3 | 101.0 | 17.8 |
Legal expenses (AUD K) | 713.5 | 171.1 | 88.3 | 50.7 |
Share based payments (AUD K) | 257.6 | 773.9 | 202.8 | 418.5 |
Advertising and marketing (AUD K) | 226.4 | 207.3 | 442.2 | 292.2 |
Impairments and write-offs incl disposal loss (AUD K) | 3,401.6 | 0 | 889.3 | 4,873.7 |
Balance Sheet
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Total assets (AUD K) | 10,833.9 | 16,547.9 | 18,736.3 | 13,153.2 |
Cash and equivalents (AUD K) | 5,183.8 | 7,417.1 | 10,573.1 | 9,240.1 |
Trade and other receivables (AUD K) | 936.1 | 709.6 | 259.9 | 190.4 |
Inventories (AUD K) | 168.9 | 489.5 | 474.0 | 510.0 |
Goodwill and intangibles (AUD K) | 1,919.3 | 4,501.2 | 4,368.8 | 93.6 |
Exploration and evaluation asset (AUD K) | 2,238.0 | 2,451.0 | 2,278.4 | 2,278.4 |
Short-term borrowings incl convertibles (AUD K) | 6,405.0 | 4,290.7 | 77.5 | 0 |
Long-term borrowings (AUD K) | 0 | 0 | 0 | 0 |
Lease liabilities current (AUD K) | 0 | 77.2 | 61.2 | 70.4 |
Lease liabilities non-current (AUD K) | 0 | 61.2 | 0 | 234.3 |
Plant funding liability (AUD K) | 0 | 0 | 0 | 254.8 |
Total debt incl leases excl plant funding (AUD K) | 6,405.0 | 4,429.2 | 138.7 | 304.7 |
Net debt negative equals net cash (AUD K) | 1,221.2 | -2,987.9 | -10,434.3 | -8,935.4 |
Total liabilities (AUD K) | 7,946.9 | 6,789.8 | 2,392.4 | 3,660.8 |
Total equity (AUD K) | 2,887.0 | 9,758.0 | 16,344.0 | 9,492.4 |
Accumulated losses (AUD K) | -29,858.4 | -37,870.5 | -42,491.9 | -50,709.9 |
Working capital (AUD K) | -1,554.7 | 2,042.2 | 8,977.6 | 6,672.9 |
Cash Flow
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Operating cash flow (AUD K) | -3,871.1 | -4,776.3 | -2,743.0 | -2,642.8 |
Capex incl intangibles and exploration (AUD K) | 399.9 | 244.6 | 181.1 | 107.6 |
Free cash flow (AUD K) | -4,271.0 | -5,020.9 | -2,924.1 | -2,750.4 |
Equity issued for cash (AUD K) | 0 | 6,618.6 | 6,654.6 | 1,692.0 |
Convertible and seed loan proceeds (AUD K) | 3,127.1 | 2,833.2 | 0 | 0 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 |
Net change in cash (AUD K) | -1,225.5 | 2,193.9 | 3,156.0 | -1,333.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
ROE on average equity (%) | -127.9 | -127.3 | -36.6 | -70.3 |
ROA on closing assets (%) | -85.2 | -48.7 | -25.5 | -69.0 |
ROIC on invested capital (%) | -205.6 | -91.1 | -81.8 | -1,658.1 |
Current ratio (x) | 0.80 | 1.30 | 4.75 | 2.95 |
Debt to equity incl leases (x) | 2.22 | 0.45 | 0.01 | 0.03 |
Net debt to EBITDA (x) | -0.15 | 0.49 | 2.23 | 0.99 |
Interest coverage EBIT over finance costs (x) | -9.3 | -3.1 | -48.6 | -267.0 |
Asset turnover revenue over closing assets (x) | 0.044 | 0.108 | 0.079 | 0.043 |
Days sales outstanding trade receivables (days) | 256.5 | 113.7 | 58.0 | 93.5 |
Days inventory outstanding (days) | 109.6 | 136.2 | 148.9 | 290.6 |
Days payables outstanding trade payables (days) | 769.1 | 545.1 | 552.4 | 1,242.4 |
Cash conversion cycle (days) | -403.0 | -295.2 | -345.5 | -858.3 |
Share Count (millions) and Per-Share Data
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Ordinary shares on issue as reported (millions) | 1,612.4 | 3,390.0 | 5,707.8 | 258.9 |
Ordinary shares adjusted for 25 to 1 consolidation (millions) | 64.5 | 135.6 | 228.3 | 258.9 |
Weighted average shares as reported (millions) | 1,611.7 | 3,143.4 | 4,909.3 | 246.7 |
Net tangible assets per share as reported (AUD cents) | 0.26 | 0.35 | 0.169 | 2.578 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Australia revenue (AUD K) | 1,050.2 | 1,123.3 | 562.3 |
Rest of the World revenue (AUD K) | 731.5 | 364.7 | 0 |
Total revenue (AUD K) | 1,781.7 | 1,488.0 | 562.3 |
Australia share of revenue (%) | 58.9 | 75.5 | 100 |
Australia revenue growth YoY (%) | 0 | 7.0 | -49.9 |
Rest of the World revenue growth YoY (%) | 0 | -50.1 | -100 |
Revenue by Region
| Metric | FY2021 | FY2022 |
|---|---|---|
Hemp food products Australia (AUD K) | 849.8 | 379.8 |
Hemp food products Rest of World (AUD K) | 80.2 | 0 |
Chia food products Australia (AUD K) | 156.4 | 125.2 |
Chia food products Rest of World (AUD K) | 270.7 | 0 |
Other revenue Australia (AUD K) | 117.2 | 57.4 |
Other revenue Rest of World (AUD K) | 13.8 | 0 |
Revenue by Region (FY2020–FY2022)
| Metric | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Hemp seed (AUD K) | 1,594.4 | 305.8 | 121.0 |
Hemp oil (AUD K) | 26.2 | 291.8 | 108.9 |
Hemp protein (AUD K) | 58.2 | 129.4 | 94.2 |
Hemp capsules (AUD K) | 10.5 | 133.2 | 39.8 |
Hemp flour (AUD K) | 23.3 | 10.9 | 10.1 |
Hemp by-products (AUD K) | 1.7 | 57.2 | 5.8 |
Chia seed (AUD K) | 0 | 381.6 | 105.7 |
Chia oil and capsules (AUD K) | 0 | 29.8 | 14.6 |
Chia flour (AUD K) | 0 | 15.7 | 4.9 |
Other incl services (AUD K) | 67.4 | 131.0 | 57.4 |
Per-Share Data and Returns & Leverage Ratios
| Metric | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Main capital raising price adjusted (AUD per share) | 0.875 | 0.125 | 0.075 |
Main capital raising proceeds (AUD K) | 5,950.0 | 7,827.5 | 1,800.0 |
Capital Markets
| Measure | Value | Basis |
|---|---|---|
Market capitalisation | A$5.44m | 258.87m shares × A$0.021 |
Net cash (30 Jun 2022) | A$8.94m | Cash A$9.24m less lease liabilities A$0.30m |
Enterprise value | About −A$3.5m (negative) | Market cap − net cash |
P/E | Not meaningful (loss-making) | FY2022 loss A$9.08m |
EV/EBITDA | Not meaningful (negative EV and EBITDA) | — |
EV/Sales | Not meaningful (negative EV) | — |
P/B | 0.57x | A$5.44m / A$9.49m equity |
Price / net cash | 0.61x | Market valued cash at a discount, reflecting expected burn and governance discount |
Analyst Conclusions
Management guidance. None. The last forward-looking statements (April 2023 to February 2024) said that (i) a Thai asset acquisition was under detailed due diligence, (ii) outstanding financial reports would be finalised with a new auditor, HLB Mann Judd, and (iii) the company would then apply for re-quotation [ASX-ANN]. None of these steps has been publicly confirmed as completed.
Consensus growth expectations. None (no coverage).
Bull case (grounded in last disclosed data):
-
Cash shell with real cash. At the last balance sheet (June 2022) the company held A$9.24m cash and no borrowings. Even after roughly two to three years of reduced burn, some cash may remain. A clean, debt-free unlisted shell with an established shareholder register can be a vehicle for a backdoor transaction.
-
Optionality on residual assets. The A$2.28m bauxite exploration asset, the fully owned Fuss Pot brand, the Canntab JV interest (A$0.33m carrying value) and any surviving MS-strain rights give non-zero salvage value.
-
Tax-loss shelter. Accumulated losses above A$50m (unrecognised deferred tax assets of A$7.1m tax effect at FY2020) could be valuable to an acquirer of a profitable business, subject to Australian continuity-of-ownership and business tests.
Bear case:
-
No listing, no liquidity. Removal under LR 17.12 means investors cannot trade. Re-admission would need full re-compliance, a prospectus and audited accounts for missing years. The company's own 2018–2019 re-compliance took about a year and 15 supplementary prospectuses.
-
Value erosion and reporting failure. Every operating venture shrank or failed: revenue −62%, goodwill fully written off, HHC in administration, partners terminated. The company also failed to pay listing fees and lodge accounts, so the last reliable cash figure is more than three years old.
-
Governance and deregistration risk. Concentrated founder-family control and a history of related-party dealings, plus a 2026 ASIC strike-off scare, imply a high probability of eventual deregistration or minimal recovery for minority holders. deListed Australia assesses the shares as of little or no value.
Key catalysts and monitorables (next 12 months):
-
Lodgement of overdue FY2023–FY2026 financial statements with ASIC.
-
Any announcement on completion or termination of the Thai cannabis asset acquisition.
-
Any application for ASX re-admission or a reverse takeover.
-
ASIC registry status: a renewed strike-off or appointment of an external administrator would be decisive.
-
Status of the South Johnstone bauxite tenure and the Canntab JV commitments (A$0.90m outstanding at FY2022).
-
Any distribution or return of capital to shareholders from residual cash.
Concluding analyst verdict.
Cann Global Limited is a case study in failed micro-cap diversification during the 2016–2019 cannabis enthusiasm. In 2019 it converted a dormant bauxite explorer into a cannabis and health-food holding company, mostly by issuing shares: 1.15bn pre-consolidation shares valued at A$40.4m bought out minorities in Medical Cannabis Limited, and smaller share issues bought T12 and Hemp Hulling Co. Measured in revenue, the strategy peaked at A$1.78m in FY2020 and fell to A$0.56m with a negative gross margin by FY2022. Measured in shareholder value, the result was a 25:1 consolidation, accumulated losses of A$50.7m and a last traded price about 97.6% below the 2019 re-listing offer price on an adjusted basis.
The business had pockets of commercial validity: Costco listings, a chia omega-3 capsule, Canntab's tablets and a capital-light Thai services model. None reached a scale that could carry a corporate cost base running at roughly six to seven times revenue. Each venture depended on a partner (Epco, MedCan, Pharmocann, HHC), and each of those relationships failed or dissolved by mid-2022. Repeated, cheaper equity raisings and related-party arrangements further weakened minority investors' position.
The September 2022 suspension, nominally pending an acquisition, turned into an 18-month stand-off. A first transaction failed regulatory hurdles, listing fees went unpaid, financial reports were not lodged, and ASX removed the company in March 2024. The entity still exists, having survived an ASIC strike-off attempt in early 2026, and may hold some residual cash, a bauxite tenement and tax losses. However, there is no public financial information after early 2023, no trading venue and no stated plan.
Verdict: For institutional purposes, Cann Global should be treated as a non-investable, delisted shell with indeterminate and probably minimal residual equity value. Only a verified lodgement of audited accounts together with a credible re-compliance transaction would justify reassessment.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Prior roles / notes |
|---|---|---|---|
David Austin | Independent Non-Executive Chair (from 30 Aug 2021) | Director since 15 Apr 2008 | Long-standing NED; FY2021 directors' fees A$38.3k |
Sholom Feldman | Managing Director & CEO | Director since 9 Nov 2007 | Previously provided services through Australian Gemstone Mining Pty Ltd (AGMPL); took a 50% pay cut from Apr 2023 during the suspension |
Jonathan Cohen | Independent Non-Executive Director | Since 2 Jul 2019 | FY2021 directors' fees A$37.4k |
Alexander J. Neuling | Company Secretary | Since about 15 May 2019 | — |
Executive Leadership Team
| Name | Role | Tenure | Notes |
|---|---|---|---|
Pnina Feldman | Founder; Executive Chairperson | 12 Apr 2007 – 30 Aug 2021 | Controlled AGMPL. Granted 70m (pre-consolidation) shares for long service, subject to AGM approval in Nov 2021 [4E-FY21] |
Marion Lesaffre | Chief Operating Officer | 28 Aug 2020 – 24 Feb 2023 | Almost 10 years with the company before appointment as COO [4E-FY20] |
John Easterling | Non-Executive Director | 2 Jul 2019 – 31 May 2022 | Counterparty to the Olivia's Choice IP agreement (related-party, subject to shareholder approval) [4E-FY20] |
Meyer Gutnick | Non-Executive Director | 4 Mar 2014 – 2 Jul 2019 | Lent A$115.0k to the company in FY2019, repaid FY2020 [4E-FY20] |
Dr Robert Coenraads | Head Geologist | via AGMPL to FY2021, then employee | [4E-FY21] |
Andrew Kavasilas | Technical Director, Medical Cannabis Ltd | — | Identified triploid cannabis trait (Tabulum Project); director loans A$694.0k at FY2019, repaid by FY2021 |
Eli Levy | Corporate head, food division | c.2019 | [BNA] |
Directors' Remuneration
| Metric | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
KMP short-term benefits (AUD K) | 714.0 | 878.7 | 920.2 | 684.4 |
KMP share-based payments (AUD K) | 0 | 0 | 50.0 | 312.0 |
KMP total compensation (AUD K) | 714.0 | 878.7 | 970.2 | 996.4 |
AGMPL related-party services paid (AUD K) | 0 | 1,295.8 | 660.0 | 0 |
AGMPL executive services component (AUD K) | 0 | 624.0 | 624.0 | 0 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Listing / status (as known) | Relative positioning vs Cann Global |
|---|---|---|---|
Hemp foods | Hemp Foods Australia | Acquired from Elixinol by Shanghai Shunho New Materials (SHE:002565), announced 3 Feb 2020 | Established 1999; described as one of the Southern Hemisphere's largest hemp food wholesalers. Clear scale leader against CGB's food division |
Hemp foods / CBD | Elixinol (ASX: EXL) | ASX-listed | Larger hemp food and CBD brand portfolio |
Hemp foods / CBD | Ecofibre (ASX: EOF) | ASX-listed | Integrated hemp genetics, food and textiles; larger scale |
Medicinal cannabis / hemp | ECS Botanics (ASX: ECS) | ASX-listed | Licensed cultivator/manufacturer; Owler lists it as a peer of Australian Organic alongside CGB |
Medicinal cannabis | Cann Group (ASX: CAN) | ASX-listed | Licensed GMP cultivation; far larger asset base |
Medicinal cannabis | Little Green Pharma (ASX: LGP) | ASX-listed | Licensed producer with own brands |
Medicinal cannabis | Bod Australia (ASX: BDA) | ASX-listed | CBD products via TGA pathways |
Medicinal cannabis | Zelira Therapeutics (ASX: ZLD) | ASX-listed | Clinical-trial-led cannabinoid medicines |
Medicinal cannabis | AusCann Group (ASX: AC8, delisted Sep 2024) | Delisted for failing to pay listing fees | Parallel failure case: capsule formulations, similar end-state |
Natural / organic foods | Australian Organic (private) | Private | Owler lists Cann Global among its top three competitors |
Global cannabis | Canopy Growth (NASDAQ/TSX: CGC/WEED) | Listed | FY2022 (Mar-YE) net revenue C$520m; global benchmark showing sector-wide losses |
Competitor Detail
| Measure | Cann Global (FY2022) |
|---|---|
Revenue | A$0.56m [4E-FY22] |
Revenue growth | −62.2% |
Gross margin | −13.9% |
Net margin | −1,614.6% |
R&D intensity | 3.2% of revenue |
Licensed manufacturing | None owned |
Recent Developments
Strict 18-month window (April 2025 – October 2026): * Public newsflow is minimal because the company has been delisted and is not reporting.



